Imagion Biosystems Limited (IBXXF) is a publicly traded company in the Healthcare sector, operating within the Medical - Diagnostics & Research industry. The company is headquartered in San Diego, CA, United States. The current CEO is Robert Romeo Proulx.
IBXXF has IPO date of 2020-09-21, listed on the Other OTC, a market capitalization of $2.21M.
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
